CNSP (CNS Pharmaceuticals) Scaled Net Operating Assets : -1.45 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CNS Pharmaceuticals's operating assets for the quarter that ended in Sep. 2024 was $0.44 Mil. CNS Pharmaceuticals's operating liabilities for the quarter that ended in Sep. 2024 was $4.03 Mil. CNS Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2024 was $2.47 Mil. Therefore, CNS Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -1.45.

CNS Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for CNS Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals Scaled Net Operating Assets Chart

CNS Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.53

0.04

0.10

-0.17

-0.36

CNS Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.40	-2.01	-2.96	-3.41	-1.45

Competitive Comparison of CNS Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, CNS Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNS Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's Scaled Net Operating Assets falls into.

CNS Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CNS Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(1.152	-	5.832)	/	13.053
=	-0.36

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.701	-	0.549
=	1.152

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	6.133	-	0	-	0.301
=	5.832

CNS Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(0.436	-	4.026)	/	2.469
=	-1.45

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	7.409	-	6.973
=	0.436

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	4.057	-	0	-	0.031
=	4.026

CNS Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CNS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

2100 West Loop South, Suite 900, Houston, TX, USA, 77027

Website

https://www.cnspharma.com

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Executives

Christopher Downs	officer: Chief Financial Officer	31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco	director, officer: Chief Executive Officer	PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes	director	13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027